PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NICE recommends risdiplam for spinal muscular atrophy

NICE has published draft guidance recommending risdiplam (Evrysdi) as part of a managed access agreement (MAA) for the treatment of the rare genetic disorder spinal muscular atrophy (SMA). The NHS will introduce the revolutionary new treatment, tackling the leading genetic cause of death among babies and young children. Around 1500 patients in England are expected to benefit from the drug, which can be taken as syrup at home.

The MAA is a special agreement between NHS England, NHS Improvement, and the company Roche, allowing people to access treatment with risdiplam while more data is collected, addressing the uncertainties identified by the independent NICE committee. NICE will then decide whether to recommend the drug for routine use on the NHS and update guidance. Risdiplam will be available through the MAA until then.

SMA is a genetic neuromuscular disorder affecting motor neurons on the spinal cord. It causes muscle weakening and problems with movement, degenerating over time. Symptoms include weak arms and legs, movement problems, muscle tremors, bone and joint problems including an unusually curved spine and breathing difficulties.

There are several types of SMA and NICE’s draft guidance recommends risdiplam for children aged two months and older with a clinical diagnosis of SMA types 1, 2, or 3, or with pre-symptomatic SMA and one to four copies of the survival of motor neuron 2 (SMN2) gene.

NHS England chief executive Amanda Pritchard has said: “In the last three years, the NHS has revolutionised care for people with SMA, by securing access to a trio of innovative treatments – Spinraza, Zolgensma, and now risdiplam – where three years ago clinicians had no effective medicines at all.”

Dr Elizabeth Wraige consultant paediatric neurologist at Evelina London children’s hospital, part of Guy’s and St Thomas’ NHS foundation trust, stated: “This will be especially important for those with SMA who cannot receive either of the two existing treatments, Spinraza and Zolgenasma. These are very exciting times and I am sure this news will be welcomed by those families and individuals affected by SMA as well as by their clinicians.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026